Medgenics (MDGN)

[bob smith]

1
DRAFT 3
Medgenics To Present At LHA Life Sciences & Medical Technologies
Virtual Conference
MISGAV, Israel and SAN FRANCISCO (February 15, 2012) – Medgenics, Inc. (NYSE Amex:
MDGN and AIM: MEDU, MEDG) (the “Company”), the developer of a novel technology for the
sustained production and delivery of therapeutic proteins in patients using their own tissue,
today announced that Andrew L. Pearlman, Ph.D., President and Chief Executive Officer of
Medgenics, will present to investors as part of the LHA Life Sciences & Medical Technologies
Virtual Conference on Thursday, February 16, 2012, at 11:00 a.m. Eastern time.
The webcast of the Medgenics presentation will be accessible live and for 30 days at
www.medgenics.com or at the PrecisionIR event site at
http://www.investorcalendar.com/IC/CEPage.asp?ID=167330.
This virtual conference event includes 30-minute presentations with accompanying slides from
eight industry leaders, and begins at 9:00 a.m. Eastern time.
About Medgenics
Medgenics is developing and commercializing Biopump™, a proprietary tissue-based platform
technology for the sustained production and delivery of therapeutic proteins using the patient's
own skin biopsy for the treatment of a range of chronic diseases including anemia, hepatitis C
and hemophilia. Medgenics believes this approach has multiple benefits compared with current
treatments, which include regular and costly injections of therapeutic proteins.
Medgenics has three long-acting protein therapy products in development based on this
technology:
· EPODURE (now completing a Phase I/II dose-ranging trial) to produce and deliver
erythropoietin for many months from a single administration, has demonstrated elevation
and stabilization of hemoglobin levels in anemic patients for six to more than 36 months;
· INFRADURE (planning to commence a Phase I/II trial in Israel in 1H12 in hepatitis C) to
produce a sustained therapeutic dose of interferon-alpha for use in the treatment of
hepatitis;
· HEMODURE is a sustained Factor VIII therapy for the prophylactic treatment of
hemophilia, now in development.
Medgenics intends to develop its innovative products and bring them to market via strategic
partnerships with major pharmaceutical and/or medical device companies.
News Release
2
In addition to treatments for anemia, hepatitis and hemophilia, Medgenics plans to develop
and/or out-license a pipeline of future Biopump™ products targeting the large and rapidly
growing global protein therapy market, which is forecast to reach $132 billion in 2013. Other
potential applications for Biopumps™ include multiple sclerosis, arthritis, pediatric growth
hormone deficiency, obesity and diabetes.
Forward-looking Statements
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933,
Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation
Reform Act of 1995, which include all statements other than statements of historical fact, including (without limitation)
those regarding the Company's financial position, its development and business strategy, its product candidates and
the plans and objectives of management for future operations. The Company intends that such forward-looking
statements be subject to the safe harbors created by such laws. Forward-looking statements are sometimes identified
by their use of the terms and phrases such as "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning,
"expect," "believe," "will," "will likely," "should," "could," "would," "may" or the negative of such terms and other
comparable terminology. All such forward-looking statements are based on current expectations and are subject to
risks and uncertainties. Should any of these risks or uncertainties materialize, or should any of the Company's
assumptions prove incorrect, actual results may differ materially from those included within these forward-looking
statements. Accordingly, no undue reliance should be placed on these forward-looking statements, which speak only
as of the date made. The Company expressly disclaims any obligation or undertaking to disseminate any updates or
revisions to any forward-looking statements contained herein to reflect any change in the Company's expectations
with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
As a result of these factors, the events described in the forward-looking statements contained in this release may not
occur.
For further information, contact:
Medgenics, Inc.
Dr. Andrew L. Pearlman
[e-mail]
LHA
Anne Marie Fields
[e-mail]
@LHA_IR_PR
Phone: [phone]
Phone: [phone]
Abchurch Communications
Adam Michael
Joanne Shears
Jamie Hooper
[e-mail]
Phone: [phone]
Religare Capital Markets (NOMAD)
Emily Staples
Phone: [phone]
SVS Securities plc (Joint Broker)
Alex Mattey
Ian Callaway
Phone: [phone]
3
Nomura Code Securities (Joint Broker)
Jonathan Senior
Phone: [phone]
- Ends -